Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer
Related Experiment Video
Updated: Oct 3, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
J Calbó1, M Marotta, M Cascalló
1Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain.
Abstract:
Pancreatic cancer has long carried poor prognosis. The development of new therapeutic approaches is particularly urgent. Inactivation of the tumor-suppressor gene p16(INK4a/CDKN2), a specific inhibitor of the cyclin-dependent kinases CDK4 and CDK6, is the most common genetic alteration in human pancreatic cancer, making it an ideal target for gene replacement. Here we transfected tumor cells using a recombinant adenovirus containing the wt-p16 cDNA (Ad5RSV-p16). The overexpression of p16 decreased cell proliferation in all four human pancreatic tumor cell lines (NP-9, NP-18, NP-29, and NP-31). However, G1 arrest and senescence were observed in only three. In contrast, the fourth (NP-18) showed a significant increase in apoptosis. This differential behavior may be related to the differences found in the expression level of E2F-1. Experiments on subcutaneous pancreatic xenografts demonstrated the effectiveness of p16 in the inhibition of pancreatic tumor growth in vivo. Taken together, our results indicate that approaches involving p16 replacement are promising in pancreatic cancer treatment.
Insights
Gene replacement therapy using p16 (inhibitor of cyclin-dependent kinases CDK4/CDK6) shows promise for pancreatic cancer. Overexpressing p16 reduced tumor cell proliferation and inhibited tumor growth in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic cancer has a poor prognosis, necessitating novel therapeutic strategies.
- Inactivation of the p16 (INK4a/CDKN2) tumor suppressor gene is a frequent event in pancreatic cancer.
- p16 inhibits cyclin-dependent kinases CDK4 and CDK6, making it a target for gene therapy.
Purpose of the Study:
- To investigate the therapeutic potential of p16 gene replacement in pancreatic cancer.
- To evaluate the effects of p16 overexpression on pancreatic cancer cell lines and xenografts.
Main Methods:
- Transfection of human pancreatic tumor cell lines (NP-9, NP-18, NP-29, NP-31) with a recombinant adenovirus carrying wt-p16 cDNA (Ad5RSV-p16).
- Assessment of cell proliferation, G1 arrest, senescence, and apoptosis.
- Evaluation of tumor growth inhibition in subcutaneous pancreatic xenografts.
Main Results:
- p16 overexpression decreased proliferation in all tested pancreatic cancer cell lines.
- G1 arrest and senescence were observed in three cell lines, while one exhibited increased apoptosis.
- Differential cellular responses may correlate with E2F-1 expression levels.
- In vivo experiments confirmed p16's effectiveness in inhibiting pancreatic tumor growth.
Conclusions:
- p16 gene replacement is a promising therapeutic approach for pancreatic cancer.
- The study highlights the potential of targeting the p16 pathway for improved treatment outcomes.
Related Concept Videos
Inhibition of Cdk Activity
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
